Tempest Therapeutics, Inc. (TPST) · Nov 20, 2026 · Delisting

Tempest Therapeutics delisting notice follows failed capital raise

Delisting notice — Failed capital raise required to restore stockholders’ equity above $2.5M

Tempest Therapeutics received a Nasdaq delisting notice after failing to complete the capital raise needed to restore equity compliance; an appeal now buys time.

Tempest is a cash-constrained clinical-stage biotech trying to advance an in vivo CAR-T pipeline for cancer and autoimmune disease; as of September 30, 2026, it had only $0.9 million of cash, a $1.8 million stockholders’ deficit, and substantial doubt about continuing as a going concern.

The financing problem has become an actual listing threat. Nasdaq had given Tempest until November 16, 2026 to restore the $2.5 million minimum-equity requirement, but the company did not complete the required capital raise. 〔0〕 That is materially worse than the earlier deficiency notice: the company has moved from needing financing to preserve its listing to receiving a formal delisting determination.

The appeal preserves trading access, not the underlying fix. Tempest plans to request a Nasdaq Hearings Panel hearing, which should stay any immediate suspension or delisting while the appeal proceeds. 〔1〕 But the filing offers no completed financing, equity repair, or alternative compliance solution; it explicitly says the company cannot assure a successful appeal. The stay therefore buys roughly one procedural window rather than resolving the capital shortfall.

This undercuts the company’s recently presented funding story. Its November 13 update highlighted a potential equity line of up to $50 million and an approximately $2.5 million private placement, but the subsequent filing confirms that the capital raise needed for Nasdaq compliance was not completed. Against a business already dependent on external capital, losing certainty around financing also complicates the ability to keep advancing clinical programs.

Bottom line: This is a clear deterioration in Tempest’s operating and financing situation, not merely a routine Nasdaq notice. The appeal delays the consequence, but the company still needs fresh capital and a successful hearing to preserve its current listing.

What to watch next

Nasdaq Hearings Panel appeal, typically within 30–45 days

Original filing on SEC EDGAR

More Tempest Therapeutics, Inc. news

Tempest Therapeutics delisting notice follows failed capital raise | TPST Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.